Article
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
Chest - 1 Mar 2021
Schwalk Audra J, Ost David E, Saltijeral Sahara N, De La Garza Henriette, Casal Roberto F, Jimenez Carlos A, Eapen Georgie A, Lewis Jeff, Rinsurongkawong Waree, Rinsurongkawong Vadeerat, Lee Jack, Elamin Yasir, Zhang Jianjun, Roth Jack A, Swisher Stephen, Heymach John V, Grosu Horiana B
Abstract excerpt
BACKGROUND: The main goal of management in patients with non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) is palliation. Patients with MPE and actionable mutations, because their disease is expected to respond quickly and markedly to targeted therapy, are less likely than those without actionable mutations to receive definitive MPE management. Whether such management is indicated in these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.